Wasn't there a thread about a month ago that since mnta could fully categorize their product they could get a fully substitutable anda, whereas Teva may get a approval but it wouldn't be able to be substituted for the brand. Hence they would need a sales force which would be tantamount to having an approval that wouldn't be worth very much.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.